Treatment combining osimertinib with ERK5 or MEK5 inhibitors effectively curtailed the survival of osimertinib-resistant lung cancer cell lines, indicating ERK5’s role in drug resistance development in lung cancer cells [55]. The gene discussed is MAP2K5; the disease is lung carcinoma.